Evotec AG (Frankfurt:EVT) (TecDAX) today announced that its research alliance with Boehringer Ingelheim has reached a milestone, triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for pre-development studies in an inflammation and immunology programme.
Dr. Werner Lanthaler, Chief Executive Officer of Evotec, commented: "This is the tenth milestone achieved since the inception of the collaboration between Boehringer Ingelheim and Evotec in 2004, thus underlining the great success of one of the largest and most significant global research alliances between pharma and biotech. We look forward to further successes from this innovative alliance based on outstanding science and a very close relationship between Evotec and Boehringer Ingelheim's scientists."
Patient-derived organoids: Transforming cancer research and personalized medicine